Biotech Values

[DewDiligence]

EGRX submits 505b2 NDA for ready-to-use Angiomax formulation:

http://finance.yahoo.com/news/eagle-pharmaceuticals-submits-nda-ready-105000836.html

…our liquid formulation will allow for immediate administration, with no reconstitution nor initial dilution required, reducing work flow and the risk of dosing errors. We believe these attributes of our formulation can be clinically significant in critical care situations.

…Eagle’s intellectual property pertaining to RTU bivalirudin includes two issued patents and an additional patent pending at the U.S. Patent and Trademark Office.

Branded Angiomax from MDCO is lyophilized, and hence it must be reconstituted before use, exposing the hospital staffer to toxic fumes. Moreover, Angiomax is used in the ER, where the reconstitution may have to be done under time pressure by an ER nurse.